Enduring Material

- https://journals.sagepub.com/doi/full/10.1177/24755303231180508

• To learn more about he relationship between insulin resistance and disease activity in PsA and its phenotype

• The National Psoriasis Foundation designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The National Psoriasis Foundation designates this enduring material for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Most psoriatic arthritis (PsA) research and studies focus solely on the skin and joint manifestations, but there is also an increased risk of metabolic disorders, including insulin resistance (IR). Learn more about the relationship between insulin resistance and disease activity in PsA and its phenotype.

Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended

Sam Koons, NPF Staff, has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
BMS - Consulting - Relationship Has Ended

Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
• AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
• CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
• AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
• Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended

This activity is supported by educational grants from Novartis.

• The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

0 %

100 %

9/21/2023